P/B
4,1
Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
$2.1B
Market Cap • 9/25/2026
2006
(20 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
40,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,4
EPS
—
Market Cap
Market Cap
2,1B
EV
2,2B
EV/Revenue
42,2
EV/EBITDA
-7,1
EV/EBIT
-7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-21,8%
Total Yield
-21,8%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
87,1%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
429,4%
Capex/Revenue
32,4%
Capex/D&A
309,4%
Capex/OCF
-7,1%
SBC/OCF
—
% PPE
3,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
10%
CAGR Op. Income 5Y
35,5%
CAGR Net Income 5Y
24%
CAGR EPS 5Y
-5,8%
CAGR OCF 5Y
33%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
13,1
Quick Ratio
0,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!